Qualitek Labs Sets November 13 Board Meet for H1 FY27 Results

Qualitek Labs Ltd will hold a board meeting on November 13, 2026, to consider unaudited H1 FY27 results for the half year ended September 30, 2026, following FY26 consolidated revenue growth of 77% to ₹124.5 crore. The board will also consider a proposed alteration to the Memorandum of Association and an extraordinary general meeting.

When will Qualitek Labs announce H1 FY27 results?

Qualitek Labs will consider and approve its unaudited H1 FY27 financial results at a board meeting scheduled for Friday, November 13, 2026. The results will cover the six months ended September 30, 2026, and are the next disclosed financial-results event for the BSE-listed testing and inspection company.

The November 3 board-meeting intimation also said directors would consider a proposed alteration to the Memorandum of Association and the convening of an extraordinary general meeting. The available filing information does not disclose the proposed change to the Memorandum of Association or the agenda and timing of the proposed meeting of shareholders.

The announcement follows a September 22, 2026, board approval for a preferential issue of equity shares and warrants. The supplied information does not provide issue size, pricing, recipient details or the expected use of proceeds. Investors will therefore need to rely on formal exchange disclosures for details of these corporate actions.

What were Qualitek Labs' latest reported financial numbers?

Qualitek Labs reported ₹38.62 crore of net sales turnover for the quarter ended March 31, 2026, up 54.9% from ₹24.93 crore a year earlier. Total income rose to ₹38.85 crore from ₹25.08 crore, while profit after tax increased 44.8% to ₹5.20 crore from ₹3.57 crore.

Operating costs rose with the expansion in revenue. Total expenses for the March 2026 quarter stood at ₹28.60 crore, compared with ₹17.72 crore in the March 2025 quarter. EBITDA was ₹10.25 crore, up from ₹7.36 crore, and EBIT increased to ₹7.60 crore from ₹5.55 crore.

The quarterly profit figure was supported by higher operating income, although interest expense also increased to ₹1.59 crore from ₹0.79 crore. Depreciation rose to ₹2.65 crore from ₹1.81 crore. These movements are relevant because laboratory additions and acquisitions can increase both depreciation and financing costs while capacity is being expanded.

What is driving Qualitek Labs' laboratory expansion?

Qualitek Labs has outlined a ₹63 crore FY27 capital-expenditure plan for new laboratories in Gandhidham, Panipat and Bengaluru, along with EMI/EMC and analytical-testing capabilities. The company operates a testing-laboratory and inspection-services network across India, comprising 10 owned laboratories and six public-private partnership laboratories.

The proposed investment indicates that expansion of physical laboratory capacity remains a central operational focus. New capability additions in EMI/EMC and analytical testing could broaden the set of services offered, but the supplied information does not state expected commissioning dates, utilisation targets, project-wise spending or projected financial contribution.

Qualitek Labs has also grown through acquisitions, according to the company snapshot. Its BSE listing dates to January 2024 on the BSE Emerge SME platform. The combination of acquisitions, owned laboratories and PPP facilities provides important context for the increase in revenue reported in FY26 and in the March 2026 quarter.

Why will the H1 FY27 update matter to investors?

The H1 FY27 update will matter because it will show whether revenue growth has continued while the company prepares to fund its ₹63 crore expansion plan. FY26 consolidated revenue reached ₹124.5 crore, up 77% from FY25, and full-year FY26 profit was ₹8.0 crore.

Investors can compare the forthcoming half-year results with the March 2026 quarter, when revenue rose faster than profit after tax. That quarter's total expenses grew to ₹28.60 crore, while employee cost was identified as the largest FY26 operating expense at 35.9% of revenue. Other operating expenses accounted for 27.1% and materials for 13.4%.

The result release may also provide information on the financial effects of new laboratories, acquisitions and funding plans, if the company chooses to disclose them. Until the board-approved H1 FY27 statements are published, no conclusion can be drawn from the reported March quarter about the six-month period ended September 2026.

Conclusion

Qualitek Labs enters its November 13 board meeting after reporting strong growth in FY26 and in the March 2026 quarter. Revenue growth, a wider laboratory network and a stated ₹63 crore expansion programme are the key disclosed factors shaping the company's operational and financial context.

The next items to watch are the unaudited H1 FY27 results, any further details on the proposed Memorandum of Association alteration, and the planned extraordinary general meeting. Formal disclosures may also clarify progress on the preferential issue and the Gandhidham, Panipat and Bengaluru laboratory projects.